Rankings / Metabolic Health

Obicetrapib

Metabolic Health · CETP inhibitor (next-generation)

Tier A-

Reviewed by Read Off Label · Last reviewed · How we grade

investigationalawaiting-readout
7.6 / 10
Tier A-
Ev 8 Bn 8 Sf 7

Bottom line

Read Off Label grades Obicetrapib as A- (7.6/10) based on strong evidence, high benefit magnitude, and a low-med-risk safety profile.

Revival of CETP inhibition after the torcetrapib (BP/mortality) and dalcetrapib (futile) failures.

Studied, labeled, or reported-use context: 10 mg PO once daily — Investigational; not individualized guidance.

What the evidence says

Revival of CETP inhibition after the torcetrapib (BP/mortality) and dalcetrapib (futile) failures. Obicetrapib's hydrophilic structure avoids torcetrapib's off-target effects. BROADWAY trial: -32% LDL on top of max statin. Triple combo (obicetrapib + ezetimibe + statin) ranks highest in 2026 network meta for LDL/ApoB reduction. Will compete with bempedoic acid and PCSK9i for the statin-add-on niche. EMA accepted marketing-authorization applications (with Menarini) for obicetrapib monotherapy and the obicetrapib/ezetimibe fixed-dose combination; an EU regulatory decision is expected 2H 2026, which would make it the first approved CETP inhibitor. US FDA filing still pending. Jul 2026: NewAmsterdam Pharma guided to an interim analysis of the PREVAIL CVOT in Q4 2026, citing favorable blinded 2-year MACE trends (topline efficacy readout still pending, unblinded).

Mechanism

Highly selective hydrophilic CETP (cholesteryl ester transfer protein) inhibitor; blocks transfer of cholesteryl esters from HDL to ApoB-containing particles, lowering LDL/ApoB while raising HDL; differs from torcetrapib/anacetrapib in cleaner off-target profile

Studied, labeled, or reported dose & route

10 mg PO once daily

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Obicetrapib's effects?
Read Off Label rates the evidence for Obicetrapib as Strong and the benefit magnitude as high, producing an overall grade of A- (7.6/10). Revival of CETP inhibition after the torcetrapib (BP/mortality) and dalcetrapib (futile) failures.
What safety findings are reported for Obicetrapib?
Obicetrapib has a low-med risk profile in the database. Low-Med (favorable safety to date; no BP signal like torcetrapib; long-term cardiovascular outcome data pending) Legal status: Investigational (NewAmsterdam/Menarini; EMA marketing-authorization applications accepted for obicetrapib and obicetrapib/ezetimibe in primary hypercholesterolaemia, EU decision expected 2H2026; PREVAIL CVOT readout expected 2026-2027).
What doses or routes are reported for Obicetrapib?
10 mg PO once daily This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Obicetrapib work?
Highly selective hydrophilic CETP (cholesteryl ester transfer protein) inhibitor; blocks transfer of cholesteryl esters from HDL to ApoB-containing particles, lowering LDL/ApoB while raising HDL; differs from torcetrapib/anacetrapib in cleaner off-target profile

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.